Detailed understanding of the proteases that convert each of the tau isoforms into toxic fragments will be important to develop inhibitors of target proteases that may attenuate production of the most neurotoxic tau fragments that underlie specific tauopathy brain disorders. This evidence concerns the gene MAPT and tauopathy.